Market Cap | 1.64B | P/E | - | EPS this Y | -234.70% | Ern Qtrly Grth | - |
Income | -125.45M | Forward P/E | -18.93 | EPS next Y | 43.20% | 50D Avg Chg | -2.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 7.00% |
Dividend | N/A | Price/Book | 5.89 | EPS next 5Y | - | 52W High Chg | -22.00% |
Recommedations | 1.60 | Quick Ratio | 8.45 | Shares Outstanding | 81.24M | 52W Low Chg | 252.00% |
Insider Own | 3.16% | ROA | -21.83% | Shares Float | 387.17M | Beta | 0.44 |
Inst Own | 91.84% | ROE | -56.85% | Shares Shorted/Prior | 8.85M/10.70M | Price | 20.64 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 394,422 | Target Price | 35.79 |
Oper. Margin | - | Earnings Date | Aug 8 | Volume | 185,167 | Change | -3.80% |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
HC Wainwright & Co. | Buy | Oct 1, 24 |
HC Wainwright & Co. | Buy | Sep 17, 24 |
HC Wainwright & Co. | Buy | Sep 11, 24 |
Canaccord Genuity | Buy | Jul 22, 24 |
HC Wainwright & Co. | Buy | Jul 1, 24 |
Truist Securities | Buy | Jun 28, 24 |
Canaccord Genuity | Buy | Jun 27, 24 |
HC Wainwright & Co. | Buy | Jun 27, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Feb 01 | Sell | 2.22 | 36,248 | 80,471 | 2,731,624 | 02/05/24 |
Edwards Martin | Director Director | Nov 20 | Buy | 1.8370 | 33,736 | 61,973 | 144,800 | 11/22/23 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Nov 01 | Sell | 1.92 | 58,752 | 112,804 | 2,840,640 | 11/03/23 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Aug 03 | Sell | 2.51 | 80,144 | 201,161 | 2,872,528 | 08/07/23 |
ZACCARDELLI DAVID | President and CEO President and CEO | Aug 03 | Sell | 2.5 | 275,888 | 689,720 | 16,431,800 | 08/07/23 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | Aug 03 | Sell | 2.5 | 275,888 | 689,720 | 15,521,248 | 08/07/23 |
Poll Claire | General Counsel General Counsel | Aug 03 | Sell | 2.5 | 48,472 | 121,180 | 1,907,367 | 08/07/23 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | Aug 01 | Sell | 2.64 | 179,648 | 474,271 | 15,797,136 | 08/03/23 |
Poll Claire | General Counsel General Counsel | Aug 01 | Sell | 2.64 | 31,552 | 83,297 | 1,955,839 | 08/03/23 |
ZACCARDELLI DAVID | President and CEO President and CEO | Aug 01 | Sell | 2.64 | 179,648 | 474,271 | 16,707,688 | 08/03/23 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Aug 01 | Sell | 2.64 | 33,464 | 88,345 | 2,952,672 | 08/03/23 |
ORBIMED ADVISORS LLC | Director Director | May 11 | Sell | 21.47 | 482,913 | 10,368,142 | 3,777,778 | 05/15/23 |
Gupta Rishi | Director Director | May 11 | Sell | 21.47 | 482,913 | 10,368,142 | 3,777,778 | 05/15/23 |
Poll Claire | General Counsel General Counsel | May 01 | Sell | 2.5759 | 80,376 | 207,041 | 1,979,063 | 05/03/23 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | May 01 | Sell | 2.61 | 106,176 | 277,119 | 2,971,136 | 05/03/23 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | May 01 | Sell | 2.5759 | 455,528 | 1,173,395 | 15,976,784 | 05/03/23 |
ZACCARDELLI DAVID | President and CEO President and CEO | May 01 | Sell | 2.5759 | 455,536 | 1,173,415 | 16,887,336 | 05/03/23 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | Feb 01 | Sell | 2.5572 | 413,168 | 1,056,553 | 16,432,312 | 02/03/23 |
ZACCARDELLI DAVID | President and CEO President and CEO | Feb 01 | Sell | 2.5572 | 432,928 | 1,107,083 | 17,342,872 | 02/03/23 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Jan 20 | Sell | 2.54 | 118,712 | 301,528 | 3,077,312 | 02/03/23 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Jan 20 | Option | 0 | 105,000 | 3,196,024 | 02/03/23 | |
Poll Claire | General Counsel General Counsel | Jan 20 | Sell | 2.59 | 152,000 | 393,680 | 774,256 | 02/03/23 |
Poll Claire | General Counsel General Counsel | Jan 20 | Option | 0 | 178,800 | 2,211,439 | 02/03/23 | |
Poll Claire | General Counsel General Counsel | Nov 21 | Sell | 2.69 | 240,000 | 645,600 | 774,256 | 12/27/22 |
ORBIMED ADVISORS LLC | Director Director | Dec 22 | Sell | 22.68 | 6,139,864 | 139,252,116 | 34,085,528 | 12/27/22 |
Gupta Rishi | Director Director | Dec 22 | Sell | 22.68 | 6,139,864 | 139,252,116 | 34,085,528 | 12/27/22 |
ZACCARDELLI DAVID | President and CEO President and CEO | Aug 09 | Sell | 1.75 | 600,000 | 1,050,000 | 15,263,560 | 08/11/22 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | Aug 09 | Sell | 1.75 | 600,000 | 1,050,000 | 14,313,496 | 08/11/22 |
ZACCARDELLI DAVID | President and CEO President and CEO | May 03 | Sell | 0.4956 | 32,904 | 16,307 | 16,351,328 | 05/05/22 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | May 03 | Sell | 0.4923 | 28,752 | 14,155 | 2,461,224 | 05/05/22 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | May 03 | Sell | 0.4956 | 12,512 | 6,201 | 15,381,520 | 05/05/22 |
Rickard Kathleen A. | Chief Medical Office.. Chief Medical Officer | Apr 08 | Sell | 0.56 | 172,520 | 96,611 | 2,546,408 | 04/12/22 |
Deschamps Lisa | Director Director | Feb 01 | Sell | 0.7775 | 11,664 | 9,069 | 70,320 | 02/03/22 |
ZACCARDELLI DAVID | President and CEO President and CEO | Feb 01 | Sell | 0.73 | 52,056 | 38,001 | 16,839,096 | 02/03/22 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | Feb 01 | Sell | 0.76 | 10,416 | 7,916 | 15,826,160 | 02/03/22 |
ZACCARDELLI DAVID | President and CEO President and CEO | Nov 01 | Sell | 0.64 | 52,056 | 33,316 | 16,845,352 | 11/03/21 |
Hahn Mark W | Chief Financial Offi.. Chief Financial Officer | Nov 01 | Sell | 0.65 | 10,416 | 6,770 | 15,991,120 | 11/03/21 |